Floatz Rating
C38/100
Confidence
Indicative
Sponsor
iCell Gene Therapeutics
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03795779CT.gov CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cll1-cd33 ccar t cells (this asset) | iCell Gene Therapeutics | Early P1 | C · 38 |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2/3 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2/3 | BB |
| Fludarabine | Sawa Ito, MD | P4 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
| Cyclosporin A | City of Hope Medical Center | P3 | BB |
| Nivestim | City of Hope Medical Center | P3 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2/3 | BB |
+42 more in the Myeloproliferative Neoplasm cohort
Other indications for cll1-cd33 ccar t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P1 | CC · 41 |
| Chronic Myeloid Leukemia | — | Early P1 | C · 38 |
| Hematopoietic And Lymphoid Cell Neoplasm | — | Early P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cll1-cd33 ccar t cells in Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cll1-cd33-ccar-t-cells-myeloproliferative-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →